INVESTOR RELATIONS

Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
NK (Common Stock) $5.52 - 0.03 (0.54%)
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference

Aug 07, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Aug. 7, 2017-- NantKwest (Nasdaq:NK), a l

Read More

NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies

Jul 31, 2017 | Press Releases

42% Of Patents Exhibited A Response, With Two Complete Responses In A Phase 1 S

Read More

NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong R

Jul 25, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Jul. 25, 2017-- NantKwest Inc. (Nasdaq:NK

Read More

Upcoming Events
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.